Join the Ozempic group to help and get support from people like you.
Ozempic News (Page 7)
Biden Seeks Coverage for GLP-1 RA Medications by Medicare, Medicaid
TUESDAY, Nov. 26, 2024 – The Biden administration is proposing Medicare and Medicaid coverage for glucagon-like peptide 1 receptor agonist (GLP-1 RA) obesity medications like semaglutide (Wegovy)...
Study Finds GLP-1 Meds, such as Ozempic, Wegovy, Can Also Help the Kidneys
TUESDAY, Nov. 26, 2024 – The potential health benefits of GLP-1 diabetes and weight loss meds keep piling up: New research shows they may also shield your kidneys from harm. In the largest study to...
Biden Will Move to Have Medicare, Medicaid Cover GLP-1 Weight-Loss Meds, such as Wegovy, Zepbound
TUESDAY, Nov. 26, 2024 – The outgoing Biden administration will propose that pricey GLP-1 obesity medications such as semaglutide (Wegovy), and tirzepatide (Zepbound) be covered by Medicare and...
Stroke Guidelines Updated, With Focus on Women and GLP-1s
MONDAY, Nov. 25, 2024 – Women, especially those who had high blood pressure during pregnancy or entered menopause before age 45, are among those with a greater risk for stroke. They and other...
Taking a GLP-1 Medication? Here's Tips to Holiday Eating
SATURDAY, Nov. 23, 2024 – So, you have managed to shed 30 pounds with the help of one of the new blockbuster GLP-1 drugs, but as the holidays near you worry about how to handle gatherings where...
Meds Like Ozempic Are Causing Folks to Waste More Food
FRIDAY, Nov. 22, 2024 – America's kitchen trash bins are receiving more unwanted food as appetites falter among people taking GLP-1 weight-loss meds, a new study shows. GLP-1s like Ozempic, Wegovy,...
AHA: Half of U.S. Adults Are Eligible for Treatment With Semaglutide
FRIDAY, Nov. 22, 2024 – More than half of all U.S. adults are eligible for semaglutide therapy, according to a research letter published online Nov. 18 in JAMA Cardiology to coincide with the ...
Semaglutide, Liraglutide May Reduce Hospitalization Risk for Alcohol Use Disorder
FRIDAY, Nov. 22, 2024 – Semaglutide and liraglutide are associated with a reduced risk for hospitalization due to alcohol use disorder (AUD), according to a study published online Nov. 13 in JAMA...
Glucagon-Like Peptide-1 Receptor Agonists May Reduce Alcohol Consumption
THURSDAY, Nov. 21, 2024 – Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use may reduce alcohol consumption and improve outcomes in some individuals, according to a study published online Nov....
More Than Half of U.S. Adults Could Be Candidates for Ozempic
TUESDAY, Nov. 19, 2024 – More than half of all American adults, almost 137 million people, could be candidates for the blockbuster GLP-1 drug semaglutide, a new analysis finds. Sold as Ozempic for...
Diabetes Meds Metformin, GLP-1s Can Also Curb Asthma
MONDAY, Nov. 18, 2024 – Drugs already taken by millions of diabetes patients appear to also help slash asthma attacks by up to 70%, new British research shows. The two drugs are metformin, one of...
More Evidence That GLP-1 Meds Curb Alcohol Abuse
FRIDAY, Nov. 15, 2024 – There have been a slew of studies recently supporting the notion that the same mechanisms that help folks lose weight with Ozempic and its kin also work to curb problem...
ASH: GLP-1 RA Use Tied to Lower Rate of Venous Thromboembolism in Diabetes
THURSDAY, Nov. 14, 2024 – For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a lower risk for venous thromboembolism (VTE),...
Ozempic Could Help Curb Alcoholism
WEDNESDAY, Nov. 13, 2024 – The blockbuster GLP-1 drug semaglutide (Ozempic, Wegovy) could curb drinking for people battling alcohol use disorder, helping them to avoid crises that require...
AHA: GLP-1 RA, SGLT-2i Use Can Lower Risk for MI, Recurrent Stroke in Stroke Survivors
TUESDAY, Nov. 12, 2024 – For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with reduced...
Further information
Related condition support groups
Weight Loss (Obesity / Overweight), Chronic Kidney Disease, Cardiovascular Risk Reduction, Diabetes, Type 2